aluates Reports

$ 0.0

Automative

Global End-Stage Kidney Disease Treatment Market Research Report 2025

Published Date: September 2025

Report Code: QYRE-Auto-8P6309

Global End Stage Kidney Disease Treatment Market Insights Forecast to 2028

BUY CHAPTERS

Global End-Stage Kidney Disease Treatment Market Research Report 2025

Code: QYRE-Auto-8P6309

Report

September 2025

Pages:78

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

BLR Bio LLC

CTI BioPharma Corp

F Hoffmann La Roche Ltd

Novartis

Prolong Pharmaceuticals LLC

VESSL Therapeutics Ltd

End-Stage Kidney Disease Treatment Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

End-Stage Kidney Disease Treatment Market

The global market for End-Stage Kidney Disease Treatment was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for End-Stage Kidney Disease Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding End-Stage Kidney Disease Treatment.

The End-Stage Kidney Disease Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global End-Stage Kidney Disease Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the End-Stage Kidney Disease Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of End-Stage Kidney Disease Treatment Market Report

Report Metric	Details
Report Name	End-Stage Kidney Disease Treatment Market
CAGR	5%
Segment by Type	MK-3866 Pacritinib Sanguinate Tesidolumab Others
Segment by Application	Clinic Hospital Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	BLR Bio LLC, CTI BioPharma Corp, F. Hoffmann-La Roche Ltd, Novartis AG, Prolong Pharmaceuticals LLC, VESSL Therapeutics Ltd
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of End-Stage Kidney Disease Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the End-Stage Kidney Disease Treatment Market report?

Ans: The main players in the End-Stage Kidney Disease Treatment Market are BLR Bio LLC, CTI BioPharma Corp, F. Hoffmann-La Roche Ltd, Novartis AG, Prolong Pharmaceuticals LLC, VESSL Therapeutics Ltd

What are the Application segmentation covered in the End-Stage Kidney Disease Treatment Market report?

Ans: The Applications covered in the End-Stage Kidney Disease Treatment Market report are Clinic, Hospital, Others

What are the Type segmentation covered in the End-Stage Kidney Disease Treatment Market report?

Ans: The Types covered in the End-Stage Kidney Disease Treatment Market report are MK-3866, Pacritinib, Sanguinate, Tesidolumab, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global End-Stage Kidney Disease Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 MK-3866

1.2.3 Pacritinib

1.2.4 Sanguinate

1.2.5 Tesidolumab

1.2.6 Others

1.3 Market by Application

1.3.1 Global End-Stage Kidney Disease Treatment Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Clinic

1.3.3 Hospital

1.3.4 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global End-Stage Kidney Disease Treatment Market Perspective (2020-2031)

2.2 Global End-Stage Kidney Disease Treatment Growth Trends by Region

2.2.1 Global End-Stage Kidney Disease Treatment Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 End-Stage Kidney Disease Treatment Historic Market Size by Region (2020-2025)

2.2.3 End-Stage Kidney Disease Treatment Forecasted Market Size by Region (2026-2031)

2.3 End-Stage Kidney Disease Treatment Market Dynamics

2.3.1 End-Stage Kidney Disease Treatment Industry Trends

2.3.2 End-Stage Kidney Disease Treatment Market Drivers

2.3.3 End-Stage Kidney Disease Treatment Market Challenges

2.3.4 End-Stage Kidney Disease Treatment Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top End-Stage Kidney Disease Treatment Players by Revenue

3.1.1 Global Top End-Stage Kidney Disease Treatment Players by Revenue (2020-2025)

3.1.2 Global End-Stage Kidney Disease Treatment Revenue Market Share by Players (2020-2025)

3.2 Global End-Stage Kidney Disease Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by End-Stage Kidney Disease Treatment Revenue

3.4 Global End-Stage Kidney Disease Treatment Market Concentration Ratio

3.4.1 Global End-Stage Kidney Disease Treatment Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by End-Stage Kidney Disease Treatment Revenue in 2024

3.5 Global Key Players of End-Stage Kidney Disease Treatment Head office and Area Served

3.6 Global Key Players of End-Stage Kidney Disease Treatment, Product and Application

3.7 Global Key Players of End-Stage Kidney Disease Treatment, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 End-Stage Kidney Disease Treatment Breakdown Data by Type

4.1 Global End-Stage Kidney Disease Treatment Historic Market Size by Type (2020-2025)

4.2 Global End-Stage Kidney Disease Treatment Forecasted Market Size by Type (2026-2031)

5 End-Stage Kidney Disease Treatment Breakdown Data by Application

5.1 Global End-Stage Kidney Disease Treatment Historic Market Size by Application (2020-2025)

5.2 Global End-Stage Kidney Disease Treatment Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America End-Stage Kidney Disease Treatment Market Size (2020-2031)

6.2 North America End-Stage Kidney Disease Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America End-Stage Kidney Disease Treatment Market Size by Country (2020-2025)

6.4 North America End-Stage Kidney Disease Treatment Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe End-Stage Kidney Disease Treatment Market Size (2020-2031)

7.2 Europe End-Stage Kidney Disease Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe End-Stage Kidney Disease Treatment Market Size by Country (2020-2025)

7.4 Europe End-Stage Kidney Disease Treatment Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific End-Stage Kidney Disease Treatment Market Size (2020-2031)

8.2 Asia-Pacific End-Stage Kidney Disease Treatment Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific End-Stage Kidney Disease Treatment Market Size by Region (2020-2025)

8.4 Asia-Pacific End-Stage Kidney Disease Treatment Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America End-Stage Kidney Disease Treatment Market Size (2020-2031)

9.2 Latin America End-Stage Kidney Disease Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America End-Stage Kidney Disease Treatment Market Size by Country (2020-2025)

9.4 Latin America End-Stage Kidney Disease Treatment Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa End-Stage Kidney Disease Treatment Market Size (2020-2031)

10.2 Middle East & Africa End-Stage Kidney Disease Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa End-Stage Kidney Disease Treatment Market Size by Country (2020-2025)

10.4 Middle East & Africa End-Stage Kidney Disease Treatment Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 BLR Bio LLC

11.1.1 BLR Bio LLC Company Details

11.1.2 BLR Bio LLC Business Overview

11.1.3 BLR Bio LLC End-Stage Kidney Disease Treatment Introduction

11.1.4 BLR Bio LLC Revenue in End-Stage Kidney Disease Treatment Business (2020-2025)

11.1.5 BLR Bio LLC Recent Development

11.2 CTI BioPharma Corp

11.2.1 CTI BioPharma Corp Company Details

11.2.2 CTI BioPharma Corp Business Overview

11.2.3 CTI BioPharma Corp End-Stage Kidney Disease Treatment Introduction

11.2.4 CTI BioPharma Corp Revenue in End-Stage Kidney Disease Treatment Business (2020-2025)

11.2.5 CTI BioPharma Corp Recent Development

11.3 F. Hoffmann-La Roche Ltd

11.3.1 F. Hoffmann-La Roche Ltd Company Details

11.3.2 F. Hoffmann-La Roche Ltd Business Overview

11.3.3 F. Hoffmann-La Roche Ltd End-Stage Kidney Disease Treatment Introduction

11.3.4 F. Hoffmann-La Roche Ltd Revenue in End-Stage Kidney Disease Treatment Business (2020-2025)

11.3.5 F. Hoffmann-La Roche Ltd Recent Development

11.4 Novartis AG

11.4.1 Novartis AG Company Details

11.4.2 Novartis AG Business Overview

11.4.3 Novartis AG End-Stage Kidney Disease Treatment Introduction

11.4.4 Novartis AG Revenue in End-Stage Kidney Disease Treatment Business (2020-2025)

11.4.5 Novartis AG Recent Development

11.5 Prolong Pharmaceuticals LLC

11.5.1 Prolong Pharmaceuticals LLC Company Details

11.5.2 Prolong Pharmaceuticals LLC Business Overview

11.5.3 Prolong Pharmaceuticals LLC End-Stage Kidney Disease Treatment Introduction

11.5.4 Prolong Pharmaceuticals LLC Revenue in End-Stage Kidney Disease Treatment Business (2020-2025)

11.5.5 Prolong Pharmaceuticals LLC Recent Development

11.6 VESSL Therapeutics Ltd

11.6.1 VESSL Therapeutics Ltd Company Details

11.6.2 VESSL Therapeutics Ltd Business Overview

11.6.3 VESSL Therapeutics Ltd End-Stage Kidney Disease Treatment Introduction

11.6.4 VESSL Therapeutics Ltd Revenue in End-Stage Kidney Disease Treatment Business (2020-2025)

11.6.5 VESSL Therapeutics Ltd Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

BLR Bio LLC

CTI BioPharma Corp

F Hoffmann La Roche Ltd

Novartis

Prolong Pharmaceuticals LLC

VESSL Therapeutics Ltd

List of Tables

Table 1. Global End-Stage Kidney Disease Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of MK-3866

Table 3. Key Players of Pacritinib

Table 4. Key Players of Sanguinate

Table 5. Key Players of Tesidolumab

Table 6. Key Players of Others

Table 7. Global End-Stage Kidney Disease Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 8. Global End-Stage Kidney Disease Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 9. Global End-Stage Kidney Disease Treatment Market Size by Region (2020-2025) & (US$ Million)

Table 10. Global End-Stage Kidney Disease Treatment Market Share by Region (2020-2025)

Table 11. Global End-Stage Kidney Disease Treatment Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 12. Global End-Stage Kidney Disease Treatment Market Share by Region (2026-2031)

Table 13. End-Stage Kidney Disease Treatment Market Trends

Table 14. End-Stage Kidney Disease Treatment Market Drivers

Table 15. End-Stage Kidney Disease Treatment Market Challenges

Table 16. End-Stage Kidney Disease Treatment Market Restraints

Table 17. Global End-Stage Kidney Disease Treatment Revenue by Players (2020-2025) & (US$ Million)

Table 18. Global End-Stage Kidney Disease Treatment Market Share by Players (2020-2025)

Table 19. Global Top End-Stage Kidney Disease Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in End-Stage Kidney Disease Treatment as of 2024)

Table 20. Ranking of Global Top End-Stage Kidney Disease Treatment Companies by Revenue (US$ Million) in 2024

Table 21. Global 5 Largest Players Market Share by End-Stage Kidney Disease Treatment Revenue (CR5 and HHI) & (2020-2025)

Table 22. Global Key Players of End-Stage Kidney Disease Treatment, Headquarters and Area Served

Table 23. Global Key Players of End-Stage Kidney Disease Treatment, Product and Application

Table 24. Global Key Players of End-Stage Kidney Disease Treatment, Date of Enter into This Industry

Table 25. Mergers & Acquisitions, Expansion Plans

Table 26. Global End-Stage Kidney Disease Treatment Market Size by Type (2020-2025) & (US$ Million)

Table 27. Global End-Stage Kidney Disease Treatment Revenue Market Share by Type (2020-2025)

Table 28. Global End-Stage Kidney Disease Treatment Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 29. Global End-Stage Kidney Disease Treatment Revenue Market Share by Type (2026-2031)

Table 30. Global End-Stage Kidney Disease Treatment Market Size by Application (2020-2025) & (US$ Million)

Table 31. Global End-Stage Kidney Disease Treatment Revenue Market Share by Application (2020-2025)

Table 32. Global End-Stage Kidney Disease Treatment Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 33. Global End-Stage Kidney Disease Treatment Revenue Market Share by Application (2026-2031)

Table 34. North America End-Stage Kidney Disease Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 35. North America End-Stage Kidney Disease Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 36. North America End-Stage Kidney Disease Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 37. Europe End-Stage Kidney Disease Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 38. Europe End-Stage Kidney Disease Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 39. Europe End-Stage Kidney Disease Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 40. Asia-Pacific End-Stage Kidney Disease Treatment Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 41. Asia-Pacific End-Stage Kidney Disease Treatment Market Size by Region (2020-2025) & (US$ Million)

Table 42. Asia-Pacific End-Stage Kidney Disease Treatment Market Size by Region (2026-2031) & (US$ Million)

Table 43. Latin America End-Stage Kidney Disease Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. Latin America End-Stage Kidney Disease Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 45. Latin America End-Stage Kidney Disease Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 46. Middle East & Africa End-Stage Kidney Disease Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 47. Middle East & Africa End-Stage Kidney Disease Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 48. Middle East & Africa End-Stage Kidney Disease Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 49. BLR Bio LLC Company Details

Table 50. BLR Bio LLC Business Overview

Table 51. BLR Bio LLC End-Stage Kidney Disease Treatment Product

Table 52. BLR Bio LLC Revenue in End-Stage Kidney Disease Treatment Business (2020-2025) & (US$ Million)

Table 53. BLR Bio LLC Recent Development

Table 54. CTI BioPharma Corp Company Details

Table 55. CTI BioPharma Corp Business Overview

Table 56. CTI BioPharma Corp End-Stage Kidney Disease Treatment Product

Table 57. CTI BioPharma Corp Revenue in End-Stage Kidney Disease Treatment Business (2020-2025) & (US$ Million)

Table 58. CTI BioPharma Corp Recent Development

Table 59. F. Hoffmann-La Roche Ltd Company Details

Table 60. F. Hoffmann-La Roche Ltd Business Overview

Table 61. F. Hoffmann-La Roche Ltd End-Stage Kidney Disease Treatment Product

Table 62. F. Hoffmann-La Roche Ltd Revenue in End-Stage Kidney Disease Treatment Business (2020-2025) & (US$ Million)

Table 63. F. Hoffmann-La Roche Ltd Recent Development

Table 64. Novartis AG Company Details

Table 65. Novartis AG Business Overview

Table 66. Novartis AG End-Stage Kidney Disease Treatment Product

Table 67. Novartis AG Revenue in End-Stage Kidney Disease Treatment Business (2020-2025) & (US$ Million)

Table 68. Novartis AG Recent Development

Table 69. Prolong Pharmaceuticals LLC Company Details

Table 70. Prolong Pharmaceuticals LLC Business Overview

Table 71. Prolong Pharmaceuticals LLC End-Stage Kidney Disease Treatment Product

Table 72. Prolong Pharmaceuticals LLC Revenue in End-Stage Kidney Disease Treatment Business (2020-2025) & (US$ Million)

Table 73. Prolong Pharmaceuticals LLC Recent Development

Table 74. VESSL Therapeutics Ltd Company Details

Table 75. VESSL Therapeutics Ltd Business Overview

Table 76. VESSL Therapeutics Ltd End-Stage Kidney Disease Treatment Product

Table 77. VESSL Therapeutics Ltd Revenue in End-Stage Kidney Disease Treatment Business (2020-2025) & (US$ Million)

Table 78. VESSL Therapeutics Ltd Recent Development

Table 79. Research Programs/Design for This Report

Table 80. Key Data Information from Secondary Sources

Table 81. Key Data Information from Primary Sources

Table 82. Authors List of This Report

List of Figures

Figure 1. End-Stage Kidney Disease Treatment Picture

Figure 2. Global End-Stage Kidney Disease Treatment Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global End-Stage Kidney Disease Treatment Market Share by Type: 2024 VS 2031

Figure 4. MK-3866 Features

Figure 5. Pacritinib Features

Figure 6. Sanguinate Features

Figure 7. Tesidolumab Features

Figure 8. Others Features

Figure 9. Global End-Stage Kidney Disease Treatment Market Size by Application (2020-2031) & (US$ Million)

Figure 10. Global End-Stage Kidney Disease Treatment Market Share by Application: 2024 VS 2031

Figure 11. Clinic Case Studies

Figure 12. Hospital Case Studies

Figure 13. Others Case Studies

Figure 14. End-Stage Kidney Disease Treatment Report Years Considered

Figure 15. Global End-Stage Kidney Disease Treatment Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 16. Global End-Stage Kidney Disease Treatment Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 17. Global End-Stage Kidney Disease Treatment Market Share by Region: 2024 VS 2031

Figure 18. Global End-Stage Kidney Disease Treatment Market Share by Players in 2024

Figure 19. Global Top End-Stage Kidney Disease Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in End-Stage Kidney Disease Treatment as of 2024)

Figure 20. The Top 10 and 5 Players Market Share by End-Stage Kidney Disease Treatment Revenue in 2024

Figure 21. North America End-Stage Kidney Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. North America End-Stage Kidney Disease Treatment Market Share by Country (2020-2031)

Figure 23. United States End-Stage Kidney Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Canada End-Stage Kidney Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. Europe End-Stage Kidney Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. Europe End-Stage Kidney Disease Treatment Market Share by Country (2020-2031)

Figure 27. Germany End-Stage Kidney Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. France End-Stage Kidney Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. U.K. End-Stage Kidney Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Italy End-Stage Kidney Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Russia End-Stage Kidney Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Nordic Countries End-Stage Kidney Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Asia-Pacific End-Stage Kidney Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Asia-Pacific End-Stage Kidney Disease Treatment Market Share by Region (2020-2031)

Figure 35. China End-Stage Kidney Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Japan End-Stage Kidney Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. South Korea End-Stage Kidney Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Southeast Asia End-Stage Kidney Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. India End-Stage Kidney Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Australia End-Stage Kidney Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Latin America End-Stage Kidney Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Latin America End-Stage Kidney Disease Treatment Market Share by Country (2020-2031)

Figure 43. Mexico End-Stage Kidney Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Brazil End-Stage Kidney Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Middle East & Africa End-Stage Kidney Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Middle East & Africa End-Stage Kidney Disease Treatment Market Share by Country (2020-2031)

Figure 47. Turkey End-Stage Kidney Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Saudi Arabia End-Stage Kidney Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. UAE End-Stage Kidney Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 50. BLR Bio LLC Revenue Growth Rate in End-Stage Kidney Disease Treatment Business (2020-2025)

Figure 51. CTI BioPharma Corp Revenue Growth Rate in End-Stage Kidney Disease Treatment Business (2020-2025)

Figure 52. F. Hoffmann-La Roche Ltd Revenue Growth Rate in End-Stage Kidney Disease Treatment Business (2020-2025)

Figure 53. Novartis AG Revenue Growth Rate in End-Stage Kidney Disease Treatment Business (2020-2025)

Figure 54. Prolong Pharmaceuticals LLC Revenue Growth Rate in End-Stage Kidney Disease Treatment Business (2020-2025)

Figure 55. VESSL Therapeutics Ltd Revenue Growth Rate in End-Stage Kidney Disease Treatment Business (2020-2025)

Figure 56. Bottom-up and Top-down Approaches for This Report

Figure 57. Data Triangulation

Figure 58. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Coronary Imaging Catheter Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-32P14840

Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Digital Platform for Chronic Kidney Disease (CKD) Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-20V18395

Tue Dec 02 00:00:00 UTC 2025

Add to Cart

Global Continuous Glucose Monitoring Sensor Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-32G20014

Tue Dec 02 00:00:00 UTC 2025

Add to Cart

Global Radioactive Iodine Ablation Therapy Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-9U20281

Tue Dec 02 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions